NADOLOL AND BENDROFLUMETHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Nadolol And Bendroflumethiazide patents expire, and when can generic versions of Nadolol And Bendroflumethiazide launch?
Nadolol And Bendroflumethiazide is a drug marketed by Impax Labs and Mylan and is included in two NDAs.
The generic ingredient in NADOLOL AND BENDROFLUMETHIAZIDE is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.
Summary for NADOLOL AND BENDROFLUMETHIAZIDE
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 2 |
Patent Applications: | 28 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NADOLOL AND BENDROFLUMETHIAZIDE at DailyMed |
Recent Clinical Trials for NADOLOL AND BENDROFLUMETHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mylan Pharmaceuticals | Phase 1 |